Calgary, Cananda-based Oncolytics Biotech has collaborated with the NCIC Clinical Trials Group (CTG) at Queen's University in Kingston, Ontario, to conduct a randomized phase II study of Reolysin in patients with recurrent or metastatic castration resistant prostate cancer.
The phase II study will build on both companies’ early preclinical and clinical prostate cancer work, as well as their growing understanding of Reolysin in combination with approved chemotherapeutic agents, according to Dr. Brad Thompson, president and CEO of Oncolytics.
The study will be an open-label, randomized, non-blinded, phase II clinical study of Reolysin given in combination with docetaxel versus docetaxel alone. Approximately 40 response evaluable patients will be enrolled in each arm.
"Third party sponsored trials remain an important part of our overall clinical strategy,” said Thompson. “We are pleased to be conducting another randomized study, especially in Canada, with an experienced and capable group like the NCIC CTG.”